Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe: a selective cholesterol absorption inhibitor.

Edith A Nutescu1, Nancy L Shapiro

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA. enutescu@uic.edu

Pharmacotherapy
|November 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Current Landscape of Anticoagulation Stewardship Implementation in the United States and Around the World: An International Survey.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Local ancestry-informed GWAS of warfarin dose requirement in African Americans identifies a CYP2C19 splicing QTL.

American journal of human genetics·2025
Same author

Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients.

Clinical pharmacology and therapeutics·2025
Same author

Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing.

Clinical and translational science·2025
Same author

Local ancestry informed GWAS of warfarin dose requirement in African Americans identifies a novel CYP2C19 splice QTL.

medRxiv : the preprint server for health sciences·2025
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Ezetimibe, a novel cholesterol absorption inhibitor, effectively lowers LDL cholesterol by 15-20% with minimal side effects. It offers a new treatment option for hypercholesterolemia, alone or with statins.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Ezetimibe represents a new class of cholesterol absorption inhibitors.
  • It targets cholesterol absorption in the small intestine.

Purpose of the Study:

  • To evaluate the efficacy and safety of ezetimibe.
  • To assess its role in managing hypercholesterolemia.

Main Methods:

  • Phase III clinical trials were conducted.
  • Ezetimibe was studied as monotherapy and in combination with statins and fenofibrate.

Main Results:

  • Ezetimibe reduced LDL cholesterol by 15-20% and increased HDL cholesterol by 2.5-5%.
  • It demonstrated a favorable safety profile, similar to placebo, with few drug interactions.

Related Experiment Videos

  • No adverse effects on triglyceride levels were observed.

    • Conclusions:

    • Ezetimibe is effective for managing hypercholesterolemia, either alone or with other lipid-lowering agents.
    • It provides a valuable option for patients needing modest LDL reduction or statin intolerance.